GSK's melanoma drugs may steal market from Roche
Linkedin

GSK's melanoma drugs may steal market from Roche

London : United Kingdom | May 28, 2012 at 5:18 AM PDT
Source: The Economic Times
XX XX
Views: Pending
 
The brokerage, which raised its price target on GSK stock on Monday, forecast combined risk-adjusted annual sales for dabrafenib and trametinib of 1.5 billion pounds ($2.35 billion)by 2020, some three times consensus expectations. MEK, have been shown in small-scale tests to curb melanoma with... FULL ARTICLE AT The Economic Times
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

More From Allvoices

Most Commented Reports



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.